HighGravityDataBoston Scientific — Jul 23, 2025 release
Fiscal 2025 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000885725-25-000039
Showing in the filing
EPS (GAAP basis)
“$0.44 to $0.46”
Period
Q3 FY2025
Measure
GAAP-tied
Source
Guidance table
All guidance in this release · 12
Net sales growth, reported basis for FY2025
“approximately 18 to 19 percent”
Net sales growth, organic basis for FY2025
“14 to 15 percent”
Earnings per Share - GAAP results for FY2025
“$1.89 to $1.93”
EPS, GAAP basis for FY2025
“$1.89 to $1.93”
Adjusted EPS for FY2025
“$2.95 to $2.99”
Earnings per Share - Adjusted results for FY2025
“$2.95 to $2.99”
Net sales growth (reported basis) for Q3 FY2025
“approximately 17 to 19 percent”
Net sales growth (organic basis) for Q3 FY2025
“12 to 14 percent”
Earnings per Share - GAAP results for Q3 FY2025
“$0.44 to $0.46”
EPS (GAAP basis) for Q3 FY2025
“$0.44 to $0.46”
Adjusted EPS for Q3 FY2025
“$0.70 to $0.72”
Earnings per Share - Adjusted results for Q3 FY2025
“$0.70 to $0.72”
Exhibit 99.1 · the passage around this item
… earlier in the release
Third quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.44 to $0.46 and estimates adjusted EPS, excluding certain charges (credits), of $0.70 to $0.72. Conference Call Information Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET. The company will webcast the call to interested parties through its website: investors.bostonscientific.com . Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website. About Boston Scientific Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X . Cautionary Statement Regarding Forward-Looking Statements This press rele
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.